DYADIC INTERNATIONAL INC Segments Disclosure

Note 9: Segment

 

The Company operates and manages its business as one reportable segment and one operating segment, which is the business of developing and commercializing synthetic protein products using the Company’s proprietary microbial platforms, including Dapibus™ and C1. The Company’s chief operating decision maker, or CODM, is the Company’s senior management team that includes the Chief Executive Officer, President & Chief Operating Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations.

 

The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The Company operates in the U.S. and Europe. All material long-lived assets of the Company reside in the U.S. For geographic information about the Company’s product revenues, see Note 1, Concentration. Long-lived assets primarily consist of operating lease right-of-use assets.

 

The CODM uses consolidated net loss to evaluate the Company’s spending and monitor budget versus actual results. The monitoring of budgeted versus actual results is used in assessing performance of the segment and in establishing resource allocation across the organization. Factors used in determining the reportable segment include the nature of the Company’s operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 1 of the notes to the consolidated financial statements included in this Annual Report on Form 10-K.

 

 

The CODM reviews cash, cash equivalents and investment securities as a measure of segment assets. As of December 31, 2025 and 2024, the Company’s cash, cash equivalents and investment securities were $8.6 million and $9.3 million, respectively.

 

The following table presents information about segment revenue, significant segment expenses and segment operating loss for the years ended December 31, 2025 and 2024:

 

Schedule of Segment Revenue, Significant Segment Expenses and Segment Operating Loss 

		2025				2024
		Years Ended December 31,
		2025				2024
Total revenues		$	3,090,345			$	3,495,389
Total cost of revenues			2,319,860				1,194,624
Research and development expenses:
Outside contracted services			1,700,828				1,503,397
Personnel related costs			343,594				414,916
Facilities, overhead, and other			41,409				67,411
General and administrative expenses:
Compensation and related expenses			2,187,798				2,308,566
Business consulting expenses			531,036				764,326
Legal and professional services			1,291,566				998,630
Other G&A expenses			889,987				995,501
Share-based compensation expenses			930,183				1,126,279
Foreign currency exchange loss			46,900				22,561
Other Income (expenses), net			(171,812	)			91,663
Net loss		$	(7,364,628	)		$	(5,809,159	)